Reviews/GLP-1 Receptor Agonists/Increase gallbladder disease risk
Safety · GLP1-SAF-05 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
The question is whether these weight-loss and diabetes drugs raise the risk of gallstones and gallbladder inflammation, and whether that risk climbs with higher doses and longer use. A large randomized trial and several patient-record studies do point to more gallstone disease on these drugs, and two record studies suggest the risk builds with longer treatment. But other equally large record studies found the opposite, that patients on the drugs had fewer gallbladder problems, and the randomized trial found no difference at all in gallbladder inflammation. No eligible study in this evidence set showed that the risk tracks with dose. Because the claim bundles together a well-supported gallstone signal with a dose-dependence claim nothing here supports and an inflammation claim the strongest study contradicts, the panel treated it as only partly carried.
The randomized SELECT trial [3] reported more gallbladder-related disorders on semaglutide than placebo (2.8% vs 2.3%, p=0.04), driven by cholelithiasis (1.4% vs 1.1%). Cohort studies [4][5][19] echo an increased gallstone signal, and [4] and [19] add a duration dimension, with [4] finding risk more evident 120 days after initiation and [19] showing associations strengthening from two to three years. However, two large cohorts [9][11] found GLP-1 users had lower rates of biliary disease, with [9] reporting cholelithiasis HR 0.81 (0.76-0.87) and cholecystitis HR 0.75 (0.66-0.85). No eligible primary study tested or demonstrated a dose-response relationship. The contested point: The evidence splits on direction: increased-risk studies [3][4][5][19] sit against two large cohorts [9][11] reporting a protective association. The dose-dependence component has no support in any eligible primary study, and the cholecystitis component is undercut by the randomized trial [3] showing identical proportions (0.6% vs 0.6%).
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Direction is contradicted by two large cohorts: Alsabbagh [9] (cholelithiasis HR 0.81, cholecystitis HR 0.75) and Kazi [11] report GLP-1 RAs associated with LOWER biliary risk, plausibly reflecting confounding by indication or weight-loss protection relative to sicker non-users.
The 'dose-dependent' clause has no support in any eligible primary study; the only dose-response analysis in the corpus ([6], a tirzepatide meta-analysis excluded by study-type) explicitly found no dose-response relationship.
Where it remains uncertain. Two large cohorts [9][11] report lower biliary risk, the randomized trial [3] found no cholecystitis difference (0.6% vs 0.6%), and no eligible study shows dose-dependence.
Aleatory
Cholecystitis and cholangitis events are uncommon (e.g. cholecystitis 0.6% vs 0.6% in [3]; cholangitis rare in [9][11]), so point estimates for the inflammation outcomes carry wide sampling variability.
Epistemic
Increased-risk studies [3][4][5][19] and protective cohorts [9][11] cannot both be right as stated; which reflects the true effect is unknown from this corpus.
Inferential
Observational comparisons against non-users may reflect that non-users are sicker or that weight loss itself alters biliary risk, rather than a drug effect.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Randomized evidence supports increased gallbladder/cholelithiasis risk but shows NO cholecystitis difference.
“Gallbladder-related disorders were more frequent with semaglutide versus placebo (2.8% vs. 2.3%; p = 0.04), mainly driven by cholelithiasis (1.4% vs. 1.1%), whereas proportions of cholecystitis were similar between groups (0.6% vs. 0.6%).”
Panel auditInternal validity: high · scope of inference: Overweight/obese patients with established cardiovascular disease; single semaglutide dose.Key limitations: cholecystitis showed no difference (0.6% vs 0.6%) · single dose, no dose-response · no sample size in abstract
Cohort supports increased biliary risk (ITT HR 1.27) and provides a duration signal.
“The increased risk of the composite outcome associated with GLP-1RAs was more evident in patients aged 〉60 years, women, and 120 days after treatment initiation.”
Panel auditInternal validity: medium · scope of inference: Asian (Taiwan) T2DM patients; GLP-1 RAs versus SGLT2i, not versus no therapy.Key limitations: on-treatment composite non-significant (1.20, 0.93-1.56) · active comparator not placebo · agent differences (liraglutide yes, dulaglutide no) · duration signal but no dose analysis
Real-world study supports modestly increased cholelithiasis risk across agents.
“The relative risk of cholelithiasis was 1.2, 1.3, and 1.4 in liraglutide, dulaglutide, and semaglutide with number needed to harm of 17.25, 14.69, and 10.96, respectively.”
Panel auditInternal validity: low · scope of inference: T2DM patients; cholelithiasis across three GLP-1 agents.Key limitations: small sample · no stated dose or duration stratification · cholelithiasis only · control group composition unclear
Large cohort DIRECTLY CONTRADICTS the claim direction, undermining corpus consistency.
“T2DM patients who were on GLP-1 RAs had lower incidence of several biliary conditions at 6 months, including cholelithiasis (HR, 0.81; 95% CI, [0.76, 0.87]), cholecystitis (HR 0.75; [0.66, 0.85])”
Panel auditInternal validity: medium · scope of inference: T2DM patients; GLP-1 RA users versus non-users at 6 months and 1 year.Key limitations: retrospective database, residual confounding · no dose or duration analysis · abstract-only conference record
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The central cholelithiasis signal is genuinely supported but is contradicted by large cohorts and the dose-dependency clause is wholly unsupported, so the full claim as worded is only weakly carried.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No GLP-1 RA dose-response analysis. The claim asserts dose-dependence, but no eligible primary study stratified biliary risk by GLP-1 RA dose; the only dose analysis available [6] was tirzepatide and found no dose-response. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A dose-stratified cohort or RCT secondary analysis comparing low- versus high-dose GLP-1 RA regimens for gallstone and cholecystitis incidence.
Open question: Does biliary disease risk on GLP-1 RAs increase with higher dose? Why it is still open: No eligible primary study in the corpus tested dose-response for GLP-1 RAs; the only dose analysis [6] concerned tirzepatide and found none.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19